Finch Therapeutics up as FDA lifts clinical hold on bacterial infection therapy

HLB Therapeutics

29/04/2022 12:56

** Shares of clinical-stage microbiome therapeutics co
 FNCH.O  up 45.2% to $3.05 premarket
    ** Stock tracking its best day on record and set to break
its nine-day losing streak, if gains hold 
    ** FNCH says U.S. FDA has removed clinical hold on
investigational new drug application for CP101, co's
experimental treatment for recurrent C. difficile infection
(CDI)  urn:newsml:reuters.com:*:nGNXdR4NB
    ** C. diff is a type of bacteria that can cause colitis, a
serious inflammation of colon; it is one of the most common
causes of health care-associated infections in U.S. hospitals
    ** On Feb 24, FDA had sent clinical hold letter requesting
additional information about Finch's SARS-CoV-2 donor screening
protocols  urn:newsml:reuters.com:*:nL4N2V45JO
    ** Co now expects to proceed with enrollment in late-stage
trial and plans to provide an update on timing of this trial and
its planned phase 1 trial of FIN-211 in children with autism
spectrum disorder and significant gastrointestinal symptoms
during Q1 results
    ** About 2.4 mln shares of Somerville, Massachusetts-based
company have traded so far, ~4,492% of their 30-DMA volume of
52,534 shares
    ** As of last close, stock down 78.9% YTD

 (Reporting by Devik Jain in Bengaluru)
 ((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2062; ;))